Document type

Report

Version

Published version

Publication date

Publication license

cc by-nc-nd (c) Badia Fernàndez, Pau, 2025
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/228684

The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease

Journal Title

Director/Tutor

Journal ISSN

Volume Title

Related resource

Abstract

Alzheimer’s disease is a severe neurodegenerative disorder that affects approximately 5% of the European population, a percentage that increases substantially among the elderly. It is also the leading cause of dementia in older adults, accounting for more than 60% of cases. Moreover, it affects not only the individual suffering from the disease but also the patient’s environment—family, friends, and acquaintances—resulting in a significant economic burden. For these reasons, Alzheimer’s disease represents a major public health issue, which becomes even more evident considering the ageing of the population.

Description

Summary of the work awarded with the first prize of the First edition of the UB Dr. Antoni i Subirana Chair Award for Research in Pharmacology for the best Master's Degree in Research in Pharmacology at the University of Barcelona

Citation

Citation

BADIA FERNÀNDEZ, Pau. The CB2R–OX2R heteromer as a new therapeutic target to combat Alzheimer’s disease. [consulted: 13 of June of 2026]. Available at: https://hdl.handle.net/2445/228684

Export metadata

JSON - METS

Share record